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Surgical Residents Make Significant Contributions to Ongoing Cancer
Research
The Department of Surgery’s research efforts have expanded greatly in recent years as evidenced by the
breadth and depth of resident research projects.
Dr. L. Andrew Shirley spent two years in the laboratory and was the Principal Investigator of a study analyzing
the role of the Dachshund (DACH1) cell fate determination pathway in various cancer types, including
breast, prostate, colorectal, and pancreatic cancers. The study, funded by a Radiation Therapy Oncology
Group Translational Research Program seed grant, was conducted under the mentorship of Richard Pestell,
MD, PhD, Director of the Kimmel Cancer Center. Dr. Shirley presented the findings at the 3rd Annual
Academic Surgical Congress and in four peer-reviewed articles.
Jonathan Brody, PhD, a specialist in pancreatic cancer research has mentored several residents in his
laboratory. Dr. Shayna Showalter explored targets in pancreatic cancer to develop novel therapeutic strategies
and examined the effect of naturally occurring Vitamin K on pancreatic cancer cells. She found that Vitamin K
actually inhibits pancreatic cancer cell growth. Dr. Showalter also used novel nanoparticle technology to
deliver diphtheria toxin specifically to pancreatic cancer cells, therefore killing the cancer cells without
effecting the growth of normal, noncancer cells. To date, she has presented the findings at three meetings,
including the American Association for Cancer Research Annual Meeting, and in three peer-reviewed articles.
Also under Dr. Brody’s mentorship, Dr. Timothy Williams investigated the tumor suppressor protein pp32
and its role in pancreatic tumor development. The research established that pp32 is low or absent in poorly
differentiated pancreatic cancer, it suppresses tumor growth when its expression is restored, and impacts the
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response of cancer cells to certain chemotherapy drugs commonly used to treat pancreatic cancer. To date, Dr.
Williams has published three peerreviewed publications on this research, presented posters at three meetings
and shares the Award for Best Research Presentation in the Department of Surgery.
Dr. Nikolai Bildzukewicz is continuing the work established by Dr. Williams on the role of pp32 in a drug
resistance pathway. However, his primary research focuses on Poly(ADP Ribose) Polymerase- 1 (PARP-1), an
enzyme found within the cell nucleus that serves many cellular functions including repair of damaged DNA.
In collaboration with John Pascal, PhD, Assistant Professor of Biochemistry and Molecular Biology, Dr.
Bildzukewicz is working with both normal and mutant forms of the enzyme in pancreatic cancer cells. His
findings include the concept of using novel agents, PARP-inhibitors, to sensitize pancreatic cancer cells to
platinum-based FDA-approved drugs. This work provides the proof-of-principle data for a proposed clinical
trial. Dr. Bildzukewicz presented the initial findings to the Philadelphia Academy of Surgery meeting in
February 2008.
In Dr. Susan Lanza-Jacoby’s laboratory, Dr. Matthew Rosen is studying the effect of Nexrutine, a natural Cox-2
inhibitor on pancreatic cancer cells, and the relationship of sirtuin (a protein involved in improving health
during calorie restriction) to pancreatic cancer. Dr. Rosen has already presented findings at two meetings
including the American Association of Cancer Research. Dr. Rosen is also the recipient of the Arnold P. Gold
Foundation Humanism and Excellence in Teaching Award.
In Dr. Hwyda Arafat’s laboratory, Dr. Jennifer Sullivan is analyzing how nictotine exposure contributes to the
aggressive nature of pancreatic cancer. Her research focuses on the expression of a protein, Osteopontin-C,
which appears to be increased in patients with pancreatic cancer, especially those with a history of smoking.
This protein could be a potential target for future therapy.
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The Spring of 2009 represents an exciting 
time here in the Department of Surgery. 
Despite the turbulent economic times, 
our clinical footprint has grown nicely, 
averaging a 5 to 12% increase per year for 
the last three years. Newer programs such 
as our minimally invasive esophagectomy 
and pancreatectomy programs, our 
bariatric surgery program, our mechanical 
heart support program, and our thriving 
acute care surgery (and intensivist) 
program are examples of success stories.
We have received good news on the 
research front. Our residents and faculty 
just completed a very busy Fall and Winter, 
when well over a dozen presentations were 
made at national fora, such as the Southern 
Surgical, the 4th Academic Surgical 
Congress, the Southeastern Surgical, and 
the American Hepato-Pancreato-Biliary 
Association, amongst others. Additionally, 
we are delighted to have recently been 
notified of major grant awards to Drs. 
Lanza-Jacoby and Tulenko, representing 
NIH dollars into the Department. Our clinical 
research has grown nicely, and the addition 
of Sharon Molotsky, RN, BSN, CCRC as our 
Clinical Research Nurse Project Manager 
will do much to ensure the attention to 
detail needed for our clinical trials.
My thanks go out to all members of the 
Department for their enthusiasm, hard 
work, clinical expertise and academic 
performance over the last several years. 
It has been wonderful to see Jefferson’s 
stature rise amongst other academic 
medical centers, as we have added faculty, 
increased our clinical volumes, added 
new clinical programs, and raised the 
research profile (both for our basic science 
researchers and for our clinicians).
New faculty, upgrades to the Intensive 
Care Unit (ICU), and multiple new trials 
and studies are just some of the changes 
underway in the Acute Care Surgery 
Division. The addition of Jay Jenoff, MD, 
and Niels Martin, MD, brings the Division 
team to seven faculty, strengthening its 
intensivist program, which makes an 
attending acute care surgeon available 24 
hours a day, 7 days a week.
Drs. Jenoff and Martin recently joined 
the Division after completing Fellowships in 
Traumatology and Surgical Critical Care at 
the Hospital of The University of 
Pennsylvania. Dr. Jenoff, Assistant Professor 
of Surgery and a 2005 graduate of the 
Jefferson Surgery residency program, is 
Board Certified in both surgery and critical 
care medicine. Dr. Martin, a 2006 graduate 
of Jefferson’s residency program is also 
Board Certified in surgery and critical care 
medicine and has been named the Associate 
Program Director of Graduate Education.
As part of Jefferson’s commitment to 
continually improving the care and 
experience of patients, the hospital is 
building a new, state-of-the-art ICU facility 
in the Gibbon Building on Jefferson’s 
Center City campus. Construction is 
expected to be completed during this year 
and will add to the existing ICU. The new 
space will accommodate 34 beds, half of 
which will be dedicated to surgical patients. 
“This fully functional ICU will have the 
most advanced technology, tools and 
instruments available,” says Dr. Martin, “so 
that we can respond to a patient’s needs, 
from pre- and post-operative care to 
bedside procedures, under ideal conditions 
with the optimal equipment.”
“Like any professional team, each 
member plays an important role,” says Dr. 
Acute Care Surgery Expands  
its Faculty, Facilities & Research
Residency Program graduates, Drs. Jay Jenoff and Niels Martin, have returned to Jefferson  
as Assistant Professors in the Acute Care Surgery Division.
Overview Clinical Integration
Dr. Joshua Curtin in the  
New Transplant Laboratory
Joshua Curtin, PhD, is a 
research fellow in the lab 
of Cataldo Doria, MD, PhD, 
focusing on the regulation 
of tumor cell growth and 
division, primarily in the liver.  
He examines how molecular 
components of cellular signaling 
pathways function to regulate 
cell growth and cell death. 
Dr. Curtin’s doctoral research studied the 
actions of natural derivatives of Vitamin A 
known as tumor cell differentiators. Derivatives 
of Vitamin A are a class of compounds known 
as retinoids, which have been shown to  
prevent the unchecked division of cancer  
cells. “Although traditional chemotherapies  
kill both the mutated cancer cells and the 
healthy normal cells,” Dr. Curtin explains,  
“this treatment stops only the cancer cells  
from dividing.”
Please Welcome
Dr. Curtin has coupled his expertise as  
a cancer biologist with his experience  
as a post-doctoral fellow in liver biology.  
“The ultimate goal,” he explains, “is to 
translate discovery in the lab into improved 
clinical treatment for patients suffering  
from liver cancer.”
To read more about this research, go to  
www.jeffersonhospital.org/transplant
Jenoff, “and our two trauma nurse 
practitioners, Alannah Ryan, CRNP, and 
Catherine Gill-Preston, CRNP, are 
absolutely invaluable to the doctors and 
patients. Their case management skills, 
skill level, and compassion for patients are 
second-to-none.”
In addition to clinical priorities, the 
Division is placing a renewed emphasis on 
research and has recently undertaken 
several clinical trials and studies. “A 
number of these new studies make 
Jefferson—and our Division in 
particular—an exciting place to be right 
now, a place to grow as a professional,” 
says Dr. Martin. In trauma, for example, 
the group is looking at new methods of 
stabilization, prevention studies, and 
resuscitation. Faculty members are also 
studying abdominal wall outcomes and 
developing new protocols, while working 
with industry representatives on device 
implementation. Research projects include 
multidisciplinary collaborations with 
Jefferson colleagues in rehabilitation and 
orthopedics. Over the next 12–15 months 
Division faculty will present findings at 
multiple national academic meetings.
For more information about the Acute Care 
Surgery Division, visit their new website at  
www.jefferson.edu/acutecare
Surgical Residents Make 
Significant Contributions to 
Ongoing Cancer Research
The Department of Surgery’s research 
efforts have expanded greatly in recent 
years as evidenced by the breadth and 
depth of resident research projects. 
Dr. L. Andrew Shirley spent two years 
in the laboratory and was the Principal 
Investigator of a study analyzing the role of 
the Dachshund (DACH1) cell fate 
determination pathway in various cancer 
types, including breast, prostate, colorectal, 
and pancreatic cancers. The study, funded 
by a Radiation Therapy Oncology Group 
Translational Research Program seed 
grant, was conducted under the 
mentorship of Richard Pestell, MD, PhD, 
Director of the Kimmel Cancer Center. Dr. 
Shirley presented the findings at the 3rd 
Annual Academic Surgical Congress and 
in four peer-reviewed articles. 
Jonathan Brody, PhD, a specialist in 
pancreatic cancer research has mentored 
several residents in his laboratory.  
Dr. Shayna Showalter explored targets  
in pancreatic cancer to develop novel 
therapeutic strategies and examined the 
effect of naturally occurring Vitamin K on 
pancreatic cancer cells. She found that 
Vitamin K actually inhibits pancreatic 
cancer cell growth. Dr. Showalter also used 
novel nanoparticle technology to deliver 
diphtheria toxin specifically to pancreatic 
cancer cells, therefore killing the cancer 
cells without effecting the growth of 
normal, noncancer cells. To date, she has 
presented the findings at three meetings, 
including the American Association for 
Cancer Research Annual Meeting, and in 
three peer-reviewed articles.
Also under Dr. Brody’s mentorship,  
Dr. Timothy Williams investigated the 
tumor suppressor protein pp32 and its role 
in pancreatic tumor development. The 
research established that pp32 is low or 
absent in poorly differentiated pancreatic 
cancer, it suppresses tumor growth when 
its expression is restored, and impacts the 
response of cancer cells to certain 
chemotherapy drugs commonly used to 
treat pancreatic cancer. To date, Dr. 
Williams has published three peer-
reviewed publications on this research, 
presented posters at three meetings and 
shares the Award for Best Research 
Presentation in the Department of Surgery. 
Dr. Nikolai Bildzukewicz is continuing 
the work established by Dr. Williams on 
the role of pp32 in a drug resistance 
pathway. However, his primary research 
focuses on Poly(ADP Ribose) Polymerase-
1 (PARP-1), an enzyme found within the 
cell nucleus that serves many cellular 
functions including repair of damaged 
DNA. In collaboration with John Pascal, 
PhD, Assistant Professor of Biochemistry 
and Molecular Biology, Dr. Bildzukewicz 
is working with both normal and mutant 
forms of the enzyme in pancreatic cancer 
cells. His findings include the concept of 
using novel agents, PARP-inhibitors, to 
sensitize pancreatic cancer cells to 
platinum-based FDA-approved drugs. 
This work provides the proof-of-principle 
data for a proposed clinical trial. Dr. 
Bildzukewicz presented the initial findings 
to the Philadelphia Academy of Surgery 
meeting in February 2008. 
In Dr. Susan Lanza-Jacoby’s laboratory, 
Dr. Matthew Rosen is studying the effect 
of Nexrutine, a natural Cox-2 inhibitor on 
pancreatic cancer cells, and the 
relationship of sirtuin (a protein involved 
in improving health during calorie 
restriction) to pancreatic cancer. Dr. 
Rosen has already presented findings at 
two meetings including the American 
Association of Cancer Research. Dr. 
Rosen is also the recipient of the Arnold 
P. Gold Foundation Humanism and 
Excellence in Teaching Award.
In Dr. Hwyda Arafat’s laboratory,  
Dr. Jennifer Sullivan is analyzing how 
nictotine exposure contributes to the 
aggressive nature of pancreatic cancer. 
Her research focuses on the expression of 
a protein, Osteopontin-C, which appears 
to be increased in patients with pancreatic 
cancer, especially those with a history of 
smoking. This protein could be a potential 
target for future therapy. Dr. Sullivan 
recently presented her data at the 
Academic Surgical Congress and a 
manuscript has been accepted for 
publication in Surgery.
Zi-Xuan (Zoe) Wang, PhD
Zi-XuanWang, PhD, is an Assistant 
Professor of Surgery, with a secondary 
appointment in the Department 
of Pathology, Anatomy, and Cell 
Biology, where she is the Assistant 
Director of the Clinical Microbiology 
Laboratory. She joined Jefferson in 
October 2008 after six years at the 
Medical College of Georgia where 
she was the Scientific Director of the 
Molecular Diagnostics Laboratory.
What is the focus of your research?
My passion is personalized medicine: 
to find out how and why certain 
therapies/medicines do or do 
not work and then to develop a 
customized approach to enhance a 
patient’s treatment. Since people can 
metabolize or respond to medicines 
in various ways, genetic analysis can 
predict a certain patient’s response, so 
that therapeutics can be administered 
and dosed optimally.
How do you use technology in  
your work?
DNA sequencing and gene chips  
have made testing individuals feasible. 
We characterize specific aspects of 
cancer and host genomes to predict 
whether a drug will be effective 
or whether serious side effects 
will emerge. Characterization of 
mutations in the patient’s genome can 
predict drug resistance and provide a 
personalized approach.
What motivates you on a day-to- 
day basis?
As a scientist, I am dedicated to 
improving the health of human 
beings and I especially enjoy working 
with the surgical faculty on pancreatic 
cancer and translational research. 
As a team, our analytical skills and 
emerging technologies have pushed 
us to the leading edge of diagnostics. 
Future collaborations with other 
Jefferson researchers will further 
advance our progress and ultimately 
improve medicine. 
Drs. Shayna Showalter, Matthew Rosen, L. Andrew Shirley, Nikolai Bildzukewicz,  
Jennifer Sullivan and Timothy Williams have made impressive contributions to cancer 
research at Jefferson as part of their surgical residency training.
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